{rfName}
Pr

Indexed in

License and use

Icono OpenAccess

Altmetrics

Grant support

Research by the authors is supported by the Instituto de Salud Carlos III under FIS/FEDER funds (PI19/00588, PI19/00815, PI20/00140, PI18/01366, PI21/00251, DTS18/00032, ERA-PerMed-JTC2018 KIDNEY ATTACK AC18/00064 and PERSTIGAN AC18/00071), FRIAT, Comunidad de Madrid en Biomedicina B2017/BMD-3686 CIFRA2-CM and by Sociedad Espanola de Nefrologia. Salary support is provided by the Ramon y Cajal program to M.D.S.N. and by grant agreement 806329 from ITN STRATEGY-CKD to C.F. Funding was also provided by the Instituto de Salud Carlos III (ISCIII) RICORS program to RICORS2040 (RD21/0005/0001), FEDER funds.

Analysis of institutional authors

Ortiz, AAuthorSanchez-Nino, MdCorresponding Author

Share

May 9, 2022
Publications
>
Editorial Material

Probiotics for kidney disease

Publicated to:Clinical Kidney Journal. 15 (11): 1981-1986 - 2022-03-29 15(11), DOI: 10.1093/ckj/sfac056

Authors: Favero, Chiara; Ortiz, Alberto; Sanchez-Nino, Maria D

Affiliations

Univ Autonoma Madrid, Dept Med, Madrid, Spain - Author
Univ Autonoma Madrid, Dept Pharmacol, Madrid, Spain - Author
Univ Autonoma Madrid, Fdn Jimenez Diaz, Lab Nefrol Expt, Inst Invest Sanitaria, Madrid, Spain - Author

Abstract

Diet has long been known to influence the course of chronic kidney disease (CKD) and may even result in acute kidney injury (AKI). Diet may influence kidney disease through a direct impact of specific nutrients on the human body through modulation of the gut microbiota composition or through metabolites generated by the gut microbiota from ingested nutrients. The potential for interaction between diet, microbiota and CKD has fueled research into interventions aimed at modifying the microbiota to treat CKD. These interventions may include diet, probiotics, prebiotics, fecal microbiota transplant and other interventions that modulate the microbiota and its metabolome. A recent report identified Lactobacillus casei Zhang from traditional Chinese koumiss as a probiotic that may protect mice from AKI and CKD and slow CKD progression in humans. Potential mechanisms of action include modulation of the gut microbiota and increased availability of short-chain fatty acids with anti-inflammatory properties and of nicotinamide. However, the clinical relevance needs validation in large well-designed clinical trials.

Keywords

Acute kidney injuryButyrateChronic kidney diseaseFibrosisInflammationMicrobiotaNicotinamidePathwayProbioticShort-chain fatty acids

Quality index

Bibliometric impact. Analysis of the contribution and dissemination channel

The work has been published in the journal Clinical Kidney Journal due to its progression and the good impact it has achieved in recent years, according to the agency WoS (JCR), it has become a reference in its field. In the year of publication of the work, 2022, it was in position 17/88, thus managing to position itself as a Q1 (Primer Cuartil), in the category Urology & Nephrology.

From a relative perspective, and based on the normalized impact indicator calculated from World Citations provided by WoS (ESI, Clarivate), it yields a value for the citation normalization relative to the expected citation rate of: 2.01. This indicates that, compared to works in the same discipline and in the same year of publication, it ranks as a work cited above average. (source consulted: ESI Nov 14, 2024)

This information is reinforced by other indicators of the same type, which, although dynamic over time and dependent on the set of average global citations at the time of their calculation, consistently position the work at some point among the top 50% most cited in its field:

  • Weighted Average of Normalized Impact by the Scopus agency: 2.7 (source consulted: FECYT Feb 2024)
  • Field Citation Ratio (FCR) from Dimensions: 7.54 (source consulted: Dimensions Jul 2025)

Specifically, and according to different indexing agencies, this work has accumulated citations as of 2025-07-17, the following number of citations:

  • WoS: 6
  • Scopus: 10
  • Europe PMC: 5

Impact and social visibility

From the perspective of influence or social adoption, and based on metrics associated with mentions and interactions provided by agencies specializing in calculating the so-called "Alternative or Social Metrics," we can highlight as of 2025-07-17:

  • The use, from an academic perspective evidenced by the Altmetric agency indicator referring to aggregations made by the personal bibliographic manager Mendeley, gives us a total of: 19.
  • The use of this contribution in bookmarks, code forks, additions to favorite lists for recurrent reading, as well as general views, indicates that someone is using the publication as a basis for their current work. This may be a notable indicator of future more formal and academic citations. This claim is supported by the result of the "Capture" indicator, which yields a total of: 23 (PlumX).

With a more dissemination-oriented intent and targeting more general audiences, we can observe other more global scores such as:

  • The Total Score from Altmetric: 11.95.
  • The number of mentions on the social network X (formerly Twitter): 25 (Altmetric).

It is essential to present evidence supporting full alignment with institutional principles and guidelines on Open Science and the Conservation and Dissemination of Intellectual Heritage. A clear example of this is:

  • The work has been submitted to a journal whose editorial policy allows open Open Access publication.
  • Assignment of a Handle/URN as an identifier within the deposit in the Institutional Repository: https://repositorio.uam.es/handle/10486/713681

Leadership analysis of institutional authors

There is a significant leadership presence as some of the institution’s authors appear as the first or last signer, detailed as follows: First Author (Favero, C) and Last Author (SANCHEZ NIÑO, MARIA DOLORES).

the author responsible for correspondence tasks has been SANCHEZ NIÑO, MARIA DOLORES.